2.39
전일 마감가:
$2.39
열려 있는:
$2.39
하루 거래량:
47,216
Relative Volume:
0.37
시가총액:
$68.98M
수익:
$875.70K
순이익/손실:
$-39.57M
주가수익비율:
-1.7805
EPS:
-1.3423
순현금흐름:
$-33.65M
1주 성능:
-5.53%
1개월 성능:
+0.63%
6개월 성능:
-8.78%
1년 성능:
-39.34%
Vistagen Therapeutics Inc Stock (VTGN) Company Profile
명칭
Vistagen Therapeutics Inc
전화
650-577-3600
주소
343 ALLERTON AVENUE, SOUTH SAN FRANCISCO
VTGN을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
VTGN
Vistagen Therapeutics Inc
|
2.39 | 73.02M | 875.70K | -39.57M | -33.65M | -1.3423 |
![]()
ONC
Beone Medicines Ltd Adr
|
258.27 | 26.01B | 3.81B | -644.79M | -669.77M | -6.24 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
445.85 | 114.30B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
AKTX
Akari Therapeutics Plc Adr
|
1.3499 | 41.83M | 0 | 0 | 0 | 0.00 |
![]()
VRNA
Verona Pharma Plc Adr
|
83.98 | 6.29B | 0 | -153.72M | -103.81M | -2.00 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
484.93 | 63.90B | 14.09B | 4.50B | 2.96B | 39.28 |
Vistagen Therapeutics Inc Stock (VTGN) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2023-12-07 | 업그레이드 | Jefferies | Hold → Buy |
2023-08-07 | 업그레이드 | Maxim Group | Hold → Buy |
2022-07-22 | 다운그레이드 | Jefferies | Buy → Hold |
2022-07-22 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
2022-07-22 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
2021-05-20 | 개시 | Robert W. Baird | Outperform |
2021-02-18 | 개시 | Jefferies | Buy |
2021-01-04 | 업그레이드 | William Blair | Mkt Perform → Outperform |
2018-06-27 | 개시 | Maxim Group | Buy |
2018-02-08 | 재확인 | Chardan Capital Markets | Buy |
2017-03-28 | 개시 | Maxim Group | Buy |
모두보기
Vistagen Therapeutics Inc 주식(VTGN)의 최신 뉴스
Vistagen Therapeutics (VTGN) Expected to Announce Quarterly Earnings on Tuesday - MarketBeat
Vistagen Therapeutics, Inc. (NASDAQ:VTGN) Shares Sold by Northern Trust Corp - Defense World
Vistagen expects phase 3 trial results by 2026 By Investing.com - Investing.com South Africa
Vistagen Therapeutics (VTGN) to Release Earnings on Tuesday - Defense World
Vistagen expects phase 3 trial results by 2026 - Investing.com India
VTGN: Vistagen Updates Timeline for Key Phase 3 Trials | VTGN St - GuruFocus
Vistagen On Track To Deliver Topline Data From Fasedienol Palisade-3 Phase 3 Trial - marketscreener.com
Major Social Anxiety Treatment Breakthrough: Phase 3 Trial Results Coming Q4 2025What to Expect - Stock Titan
Vistagen Therapeutics (NASDAQ:VTGN) Stock Price Crosses Above 50 Day Moving AverageWhat's Next? - MarketBeat
Vistagen to Present at the Jefferies 2025 Global Life Sciences Conference New York - sharewise
Vistagen Showcases Revolutionary Nose-to-Brain Drug Technology at Major Jefferies Healthcare Conference - Stock Titan
Breakthrough Nasal Spray Treatment Shows Promise for Depression and Social Anxiety, New Clinical Data Reveals - Stock Titan
Vistagen Therapeutics, Inc. (NASDAQ:VTGN) Shares Sold by Renaissance Technologies LLC - MarketBeat
254,655 Shares in Vistagen Therapeutics, Inc. (NASDAQ:VTGN) Bought by Almitas Capital LLC - MarketBeat
Renaissance Technologies LLC Has $247,000 Stake in Vistagen Therapeutics, Inc. (NASDAQ:VTGN) - Defense World
Form 8-KCurrent report - ADVFN
Nantahala Capital Management LLC Boosts Stake in Vistagen Therapeutics, Inc. (NASDAQ:VTGN) - MarketBeat
JPMorgan Chase & Co. Buys 772,228 Shares of Vistagen Therapeutics, Inc. (NASDAQ:VTGN) - MarketBeat
Press Release Distribution & PR Platform - ACCESS Newswire
JPMorgan Chase & Co. Acquires 772,228 Shares of Vistagen Therapeutics, Inc. (NASDAQ:VTGN) - Defense World
Social Anxiety Crisis: 48% of Young Adults Report Suicidal Thoughts, Treatment Gap Widens - Stock Titan
Vistagen Presents New Research on the Impact of Social Anxiety Disorder at The Anxiety and Depression Association 2025 Conference - BioSpace
Financial Survey: Vistagen Therapeutics (NASDAQ:VTGN) versus IO Biotech (NASDAQ:IOBT) - Defense World
Vistagen Therapeutics, Inc. (NASDAQ:VTGN) Shares Purchased by Blair William & Co. IL - Defense World
VTGN Stock Touches 52-Week Low at $2.21 Amid Market Challenges - Investing.com UK
VistaGen Therapeutics to Present at the Cowen and Company 39th Annual Health Care Conference on March 13, 2019 - ACCESS Newswire
Mental Disorder Treatment Market Set to Witness Significant - openPR.com
Vistagen Therapeutics (NASDAQ:VTGN) Shares Cross Above Fifty Day Moving AverageHere's Why - MarketBeat
Generalized Anxiety Disorder Treatment Market Size in 7MM - openPR.com
Vistagen Therapeutics (NASDAQ:VTGN) Share Price Passes Above 50-Day Moving Average – Should You Sell? - Defense World
Vistagen to Present at the 2025 Anxiety and Depression Association Conference - Sharewise
Groundbreaking Social Anxiety Treatment Research: Vistagen Reveals New Clinical Data at ADAA 2025 - StockTitan
Vistagen Therapeutics (NASDAQ:VTGN) Shares Cross Below 50 Day Moving AverageTime to Sell? - MarketBeat
Vistagen Therapeutics Inc (VTGN) Q3 FY2025 Earnings: EPS of -$0. - GuruFocus.com
VistaGen Therapeutics to Present at ChinaBio(R) Partnering Forum in Shanghai, China - ACCESS Newswire
Vistagen to Participate in Stifel 2025 Virtual CNS Forum - Business Wire
VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q3 2025 Earnings Call Transcript - MSN
VistaGen Therapeutics Reports Fiscal 2020 First Quarter Financial Results - accessnewswire.com
VistaGen Therapeutics to Participate in the William Blair 3rd Annual Late-Stage Therapeutics Conference on April 4, 2019 - ACCESS Newswire
Vistagen Therapeutics (NASDAQ:VTGN) Stock Price Passes Above 50 Day Moving AverageShould You Sell? - MarketBeat
Vistagen to Participate in the 45th Annual TD Cowen Healthcare Conference - StockTitan
VistaGen Therapeutics Receives Australian Patent for Treatment of Depression with AV-101 - ACCESS Newswire
Vistagen Therapeutics Inc (VTGN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):